{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003868","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.240167+00:00","generated_at":"2026-06-07T02:24:20.512027+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Setrusumab OI trials on track; alvelestat FDA alignment; leflutrozole licensed for up to $64.25M","bullets":["Setrusumab: Phase 3 Orbit study (195 patients) expected full enrollment around end Q1 2024; Cosmic study (~65 patients) expected full enrollment 1H 2024.","Phase 2 data showed 67% reduction in annualized fracture rate; additional data expected 2024.","Alvelestat: FDA aligned on Phase 3 design with SGRQ Total Score as primary endpoint; could support full U.S. approval.","Leflutrozole: global license deal with ReproNovo; Mereo received upfront payment and up to $64.25M in milestones plus tiered royalties.","Cash runway guidance reaffirmed: existing cash expected to fund operations into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003868","json":"https://secwatch.observer/filing/0001193125-24-003868.json","markdown":"https://secwatch.observer/filing/0001193125-24-003868.md","text":"https://secwatch.observer/filing/0001193125-24-003868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524003868/0001193125-24-003868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524003868/d100759d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:24:20.512027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}